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Abstract
Introduction Hypolysible fibrin clots composed of tightly packed fibers characterize patients with peripheral artery disease 
(PAD) especially those with critical limb ischemia (CLI). Little is known about the impact of a prothrombotic clot phenotype 
on restenosis following endovascular revascularization in CLI. The goal of this study was to compare fibrin clot properties 
and their determinants in CLI patients with restenosis after endovascular treatment (ET) and those free of this complication.
Methods 85 patients with CLI and restenosis within 1 year after ET on optimal pharmacotherapy and 47 PAD control 
patients without restenosis were included into the study. Plasma fibrin clot permeability (Ks, a measure of the average pore 
size in the fibrin network) and clot lysis time (CLT) with its potential determinants were determined. During follow-up, the 
composite endpoint including re-intervention, amputation and death was assessed.
Results Compared with the control group, patients with restenosis had reduced  Ks (− 9.5%, p < 0.001), prolonged CLT 
(+ 12.4%, p = 0.003), higher thrombin generation (+ 7.9%, p < 0.001) and elevated von Willebrand factor (vWF) antigen 
(+ 14.2%, p < 0.001). During a 24 months follow-up the composite endpoint occurred in 54 CLI patients with restenosis 
(63.5%) and nine control patients (19.1%, p < 0.001) with no association with baseline  Ks and CLT.
Conclusion The increased thrombin formation and unfavorable fibrin clot properties occur in patients with CLI who expe-
rienced restenosis despite optimal endovascular and pharmacological therapy.
Keywords Fibrin clot · Peripheral arterial disease · Endovascular treatment · In-stent restenosis
Highlights
• Plasma fibrin clot permeability and clot lysis time are 
non-standard but clinically useful tools for athero-
thrombotic risk assessment.
• CLI patients with restenosis after endovascular treatment 
demonstrate unfavorable clot characteristics.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1123 9-019-01826 -9) contains 
supplementary material, which is available to authorized users.
 * Tomasz Nowakowski 
 mmnowako@cyf-kr.edu.pl
 Krzysztof Piotr Malinowski 
 krzysztof.malinowski@kcri.org
 Rafał Niżankowski 
 rtn@wp.pl
 Teresa Iwaniec 
 teresaiwaniec@poczta.fm
 Anetta Undas 
 mmundas@cyf-kr.edu.pl
1 Department of Angiology, Jagiellonian University Medical 
College, 8 Skawinska St, 31-066 Krakow, Poland
2 Krakow Cardiovascular Research Institute, Krakow, Poland
3 Institute of Public Health, Faculty of Health Science, 
Jagiellonian University Medical College, Krakow, Poland
4 Department of Medicine, Jagiellonian University Medical 
College, Krakow, Poland
5 Institute of Cardiology, Jagiellonian University Medical 
College, Krakow, Poland
6 John Paul II Hospital, Krakow, Poland
541Restenosis is associated with prothrombotic plasma fibrin clot characteristics in…
1 3
• The association of prothrombotic clot features and poor 
outcomes in endovascularly treated CLI patients is not 
evident.
• Prothrombotic clot phenotype might be modified by tai-
lored pharmacotherapy especially anticoagulation which 
should be evaluated in future studies in this group of 
patients.
Introduction
Peripheral artery disease (PAD) is a common age-dependent 
disease with its prevalence up to 18–20% in patients over 
70 years of age. The prevalence of intermittent claudica-
tion is 3–7% of patients and critical limb ischemia (CLI) the 
most advanced form of PAD, associated with a drastic limi-
tation of quality of life, amputation, increased cardiovascular 
events and mortality occurs in 1–3% of patients with PAD 
with a likely rising prevalence in the future [1–5]. The 1 year 
incidence of major amputations (above the ankle), as well as 
MI or stroke in patients with CLI without revascularization 
reaches 30–50% and death occurs in up to 25% in the five 
following years [1, 6].
The most effective treatment of CLI is surgical or endo-
vascular revascularization of the endangered limb, with 
similar rates of amputations, amputation-free survival and 
mortality [7–9]. Known factors that improve outcomes of 
ET in CLI involve drug eluting stents, drug eluting bal-
loons, endovascular atherectomy, cutting balloons and ret-
rograde tibiopedal access [4, 10, 11]. It is unclear whether 
any hemostatic parameters may contribute to outcomes of 
such therapy.
Enhanced blood coagulation linked to the systematic 
inflammatory state, reflected among others by elevated 
plasma fibrinogen, is implicated in PAD and its complica-
tions [12]. The conversion of plasma fibrinogen into fibrin 
and fibrin clot formation constitute the final step of the blood 
coagulation. Fibrinogen and fibrin promote plaque growth 
[13]. Numerous environmental and genetic factors influence 
fibrin clot characteristics and plasma fibrinogen concentra-
tions and its function are of key importance [14]. Of note, 
most PAD risk factors such as diabetes, arterial hyperten-
sion, cigarette smoking, have been demonstrated as unfa-
vorable modulators of fibrin clot properties [15].
It has been shown that dense fibrin networks composed 
of thin and tightly packed fibers with relatively reduced 
susceptibility to lysis characterize PAD [16]. Altered fibrin 
clot structure and function were found in relatively young 
individuals with intermittent claudication, in the healthy 
first-degree relatives of patients with claudication and in 
premature PAD patients [17–19]. In 2011 we reported unfa-
vorable fibrin clot properties also in patients with advanced 
PAD especially in those with worse clinical outcomes during 
5 years of follow-up [20].
Until now there have been no reports assessing the impact 
of the prothrombotic clot phenotype on restenosis following 
endovascular revascularization in CLI. We hypothesized that 
PAD patients with CLI who experienced restenosis despite 
optimal endovascular and pharmacological treatment char-
acterize more prothrombotic fibrin clot properties involving 
denser fiber meshwork relatively resistant to lysis compared 
with those with good outcomes at a 1 year follow-up.
Patients and methods
Among 697 patients with CLI defined according TASC cri-
teria [1], treated endovascularly at the Department of Angi-
ology of the Jagiellonian University in Cracow between Feb-
ruary 2014 and February 2016, we screened and enrolled 
140 consecutive patients in whom symptomatic restenosis 
in the treated segment occurred over the 12 month follow-
up period.
Exclusion criteria were: recent (< 6 months) deep vein 
thrombosis, pulmonary embolism, acute coronary syndrome 
or cerebrovascular episode, known malignancy, signs of 
acute infection, end-stage renal failure and oral anticoagu-
lant therapy (International Normalized Ratio [INR] > 1.5). 
Patients with premature cessation of antiplatelet drugs 
(n = 17), with suboptimal result of the percutaneous angi-
oplasty (PTA) during the primary procedure (n = 12) and 
those with incomplete laboratory data (n = 5) were also 
excluded.
The control group comprised 47 PAD outpatients with 
similar cardiovascular risk factors treated percutaneously 
(initially 32 CLI patients and 15 non CLI patients), who 
demonstrated improvement in limb ischemia, pain relief and 
no symptoms of restenosis in the last 12 months after PTA.
CAD was defined as a history of MI, coronary interven-
tion, or hospitalization for angina symptoms. Diabetes was 
diagnosed based on the use of insulin or oral hypoglyce-
mic agents. Cerebrovascular disease was defined as a docu-
mented history of stroke or transient ischemic attack (TIA). 
Renal failure (RF) was defined as chronic kidney disease 
with estimated glomerular filtration rate [eGFR] below 
60 ml/min/1.73 m2.
Dyslipidemia was defined as a history of diagnosed and 
treated hypercholesterolemia or/and hypertriglyceridemia. 
Heart failure diagnosis was based on the hospitalization his-
tory or typical symptoms/signs and hypertension diagnosis 
was based on the history of antihypertensive treatment or 
elevated blood pressures over 140/90 mm Hg.
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Endovascular procedure and angiographic 
evaluation
All patients qualified for repeated endovascular treatment 
received dual antiplatelet therapy (aspirin 75 mg/d and clopi-
dogrel 75 mg/d or ticagrelor 90 mg BID). Patients with the 
highest thromboembolic risk qualified to endovascular treat-
ment immediately (ischemic exacerbation, rapid progression 
of ulceration/necrosis) received additionally low-molecular-
weight heparin (LMWH) at prophylactic or half-therapeu-
tic dose before ET with continuation for 4 weeks after the 
procedure.
All angiograms of primary and re-intervention were 
independently analyzed off-line by 2 experienced investiga-
tors (TN, MK) unaware of the fibrin clot data. All treated 
segments were analyzed carefully for the presence of unfa-
vorable outcome including dissection limiting vessel flow, 
peripheral emboli or stent under expansion. Stenosis was 
defined as significant based on visual inspection or when 
the degree of stenosis measured with Quantitative Vascu-
lar/Coronary Angiography (QVA/QCA) software (Siemens, 
Germany) was > 50% of lumen diameter [21].
Postprocedural follow‑up
During follow-up after the primary procedure clinical 
improvement or worsening of the treated limb were evalu-
ated in all patients. Non-invasive tests were also performed. 
Ankle-brachial index, toe-brachial index (TBI) assessment 
and duplex ultrasound imaging were performed at 1, 3, 6 
and 12 months after primary ET. Regardless of clinical 
signs and symptoms the initial diagnosis of the restenosis 
was made using non-invasive tests—primarily ultrasound 
imaging. Patients with restenosis in the previously treated 
vessel in ultrasound examination were qualified for angio-
plasty. Digital subtraction angiography (DSA) which finally 
confirmed the diagnosis of restenosis was done during the 
re-PTA procedure.
The restenosis was defined as a reoccurrence of the nar-
rowing of the lumen of a successfully treated vessel segment 
with more than 50% of artery diameter reduction in DSA.
Patients and their families were instructed about phar-
macological treatment after the procedure. They were also 
encouraged to stop smoking.
The composite endpoint included re-intervention because 
of restenosis, major amputation and cardiovascular death.
Laboratory investigations
Blood for the laboratory tests was taken in the postproce-
dural follow-up period up to 12 months after index PTA both 
in patients with restenosis and in the control group.
In the CLI patients time of blood sampling after the pri-
mary procedure was variable and was associated with the 
occurance of restenosis. The mean time of blood sampling 
in this group was the same as the mean time of the re-inter-
vention (22–23 weeks after the primary PTA). In the con-
trol group blood samples were taken 3 or 6 months after 
PTA during the follow-up visit. Blood was drawn from an 
antecubital vein with minimal stasis after an overnight fast, 
between 7 and 10 AM. In patients receiving LMWH the 
blood was collected over 12 h after the last injection.
Blood cell count, creatinine, glucose were assayed by 
routine laboratory techniques. eGFR was calculated accord-
ing to the Modification of Diet in Renal Diseases (MDRD) 
study equation. Fibrinogen was determined using the Clauss 
method and hs-CRP by the latex nephelometry (Siemens, 
Marburg, Germany). Commercially available immunoen-
zymatic assays were used to determine tissue-type plasmi-
nogen activator antigen (t-PA:Ag), plasminogen activator 
inhibitor-1 antigen (PAI-1:Ag) (both American Diagnostica, 
Stamford, CT, USA) and thrombin activatable fibrinolysis 
inhibitor antigen (TAFIa/ia) (Imubind TAFIa/ai antigen 
ELISA; American Diagnostica). Von Willebrand factor 
(vWF) antigen was measured with immunoturbidimetry 
using the STA Liatest kit (Diagnostica Stago, Asniéres, 
France). Plasminogen and α2-antiplasmin were measured 
by chromogenic assays (STA Stachrom antiplasmin and 
STA Stachrom plasminogen, Diagnostica Stago, Asniéres, 
France).
Thrombin generation was assessed using the Calibrated 
Automated Thrombogram (Thrombinoscope BV, Maastricht, 
the Netherlands) according to the manufacturer’s instruc-
tions in the 96-well plate fluorometer (Ascent Reader, Ther-
molabsystems OY, Helsinki, Finland) [22]. The area under 
the curve (AUC), as a measure of the endogenous thrombin 
potential (ETP), expressed the dynamic of thrombin genera-
tion in the plasma sample after addition of TF. Each plasma 
sample was analyzed in duplicate. All intra-assay and inter-
assay coefficients of variation were below 7%.
Plasma fibrin clot analysis
In citrated plasma (vol/vol 9:1 of 3.2% sodium citrate), the 
following variables describing plasma clot structure and lys-
ability were determined in duplicate by technicians blinded 
to the origin of the samples (intra-assay and inter-assay coef-
ficients of variation, 5–7%).
Clot permeability
Permeation properties of fibrin clots were investigated as 
previously described [23]. At a glance, after incubation 
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of 20 mmol/L calcium chloride, 1 U/mL human thrombin 
(Sigma, St. Louis, MO) and the citrated plasma, tubes con-
taining the clots were connected to a reservoir of a buffer 
(0.01 MTris, 0.1M NaCl, pH 7.5) and its volume flowing 
through the gels was measured within 60 min. A permeation 
coefficient  (Ks), indicating the pore size, was calculated from 
the equation:  Ks = Q × L × η / t × A × Δp, where Q is the flow 
rate in time t, L is the length of a fibrin gel, η is the viscosity 
of liquid (in poise), A is the cross-sectional area (in  cm2), 
and Δp is a differential pressure (in dyne/cm2).
Clot lysis time
Clot lysis time (CLT) was determined as described [24, 25]. 
Briefly, the mixture of 10000-diluted human tissue factor 
(Innovin, Siemens, Marburg, Germany), 12 µmol/l phospho-
lipid vesicles and 60 ng/ml recombinant t-PA (Boehringer 
Ingelheim, Ingelheim, Germany) was transferred to a micro-
titre plate and its turbidity was measured at 405 nm at 37 °C. 
CLT was defined as the time from the midpoint of the clear-
to-maximum-turbid transition, which represents clot forma-
tion, to the midpoint of the maximum-turbid-to-clear transi-
tion representing the clot degradation.
Statistical analysis
The study was powered to have a 90% chance of detecting a 
10% difference in CLT using a p-value of 0.05, based on the 
values of CLT. In order to demonstrate such a difference or 
greater, 32 patients were required in each group. In turn, to 
demonstrate such a difference in  Ks using a p-value of 0.05, 
at least 31 patients were required in each group.
Continuous variables are expressed as mean ± SD or 
otherwise stated (as median with IQR). Continuous vari-
ables were checked for normality using the Shapiro–Wilk 
test and compared by Student’s t-test (with correction for 
unequal variances if appropriate) when normally distributed 
or by the Mann–Whitney or Wilcoxon tests for non-normally 
distributed variables. The Pearson or Spearman rank cor-
relation coefficients were calculated to test the association 
between two variables with a normal or non-normal distribu-
tion, respectively. Odds for the 1st quartile of  Ks compared 
to the 4th and for the 4th quartile of CLT compared to the 
1st quartile were calculated using simple logistic regres-
sion. Multiple logistic regression models were constructed 
stepwise backward from variables with a p-value < 0.2 from 
simple regression models. Bayesian Information Criterion 
(BIC) was used as a target.
Fig. 1  Study patients recruitment and selection diagram
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Table 1  Characteristics of CLI 
patients with restenosis and 
control subjects
Values are given as mean ± SD or number (percentage)
BMI body mass index; CAD coronary artery disease; MI myocardial infarction; PCI percutaneous coronary 
intervention; CABG coronary by-pass graft; CVD cerebrovascular disease; TIA transient ischemic attack; 
RF renal failure; ABI ankle/brachial index; TBI toe/brachial index; ASA acetylsalicylic acid; ACEI angioten-
sin-converting enzyme inhibitor; ARB angiotensin receptor blocker; BB beta-receptor blocker; LMWH low 
molecular weight heparin; P2Y12  P2Y12 receptor inhibitor; PPI proton pump inhibitor
Restenosis group (n = 85) Controls (n = 47) p value
Age, years 69.65 ± 10.36 66.89 ± 8.46 0.14
Male gender, n (%) 49 (57.65) 33 (70.21) 0.15
BMI, kg/m2 25.49 ± 4.91 26.26 ± 3.91 0.13
Current smoking, n (%) 55 (64.71) 35 (74.47) 0.25
Dyslipidemia, n (%) 53 (62.35) 26 (55.32) 0.43
Diabetes, n (%) 38 (44.71) 23 (48.94) 0.64
Hypertension, n (%) 73 (85.88) 42 (89.36) 0.57
Heart failure, n (%) 18 (21.18) 5 (10.64) 0.13
CAD, n (%) 35 (41.18) 17 (36.17) 0.57
 MI 20 (23.53) 9 (19.15) 0.56
 PCI 13 (15.29) 7 (14.89) 0.04
 CABG 5 (5.88) 1 (2.13) 0.42
CVD, n (%) 15 (17.65) 2 (4.26) 0.027
RF, n (%) 25 (29.41) 5 (10.64) 0.013
PAD characteristic
 Rutherford class
  3, n (%) 0 (0.00) 15 (31.91) < 0.001
  4, n (%) 39 (45.88) 8 (17.02)
  5, n (%) 40 (47.06) 18 (38.30)
  6, n (%) 6 (7.06) 6 (12.77)
ABI 0.28 ± 0.46 0.64 ± 0.36
TBI 0.05 ± 0.10 0.21 ± 0.19
Treated segment
 Ilio-femoral, n (%) 9 (10.59) 10 (21.28)
 Femoro-popliteal, n (%) 44 (51.76) 17 (36.17) 0.12
 Femoro-popliteal and/or infrap-
opliteal, n (%)
32 (37.65) 20 (42.55)
Time to restenosis  (weeks) 20.75 ± 13.59 - -
Time to re-intervention, (w) 23.21 ± 14.17 - -
Medications, n (%)
 Statins 85 (100) 47 (100) 1.0
 Aspirin 85 (100) 47 (100) 1.0
 ACEI/ARB 59 (69.41) 32 (68.09) 0.87
 BB 44 (52.38) 22 (46.81) 0.54
 Calcium antagonists 26 (30.59) 16 (34.04) 0.68
 LMWH 47 (55.29) 0 (0.00) < 0.001
 P2Y12 84 (98.82) 13 (27.66) < 0.001
 PPI 73 (85.88) 19 (40.43) < 0.001
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A p-value < 0.05 was considered statistically significant. 
All calculations were done with JMP, version 13.1 (SAS 
Institute Inc., Cary, NC, USA).
Results
Patient characteristics
A total of 85 patients with in-stent restenosis/re-occlusion 
after PTA entered the final analysis (Fig. 1).
Characteristics of patients with restenosis and control 
subjects were presented in Table 1.
84 patients with restenosis (98.7%) had at least one stent 
implanted during the primary procedure and one patient 
(1.7%) had balloon angioplasty. During re-intervention 72 
(84.7%) patients were treated with stent implantation and 13 
(15.3%) with balloon angioplasty alone.
The mean time of restenosis occurrence was 21 weeks 
(3–50 weeks) and the re-intervention time in most patients 
(62.4%) was 2–3  weeks longer (p = 0.19). 32 patients 
(37.6%) required immediate intervention.
Both ABI and TBI were lower in the restenosis group. 
There was no significant difference with regard to the treated 
vascular segment of the affected limb.
Both groups did not differ in baseline routine laboratory 
investigations except for lower hemoglobin and eGFR in the 
restenosis group (Table 2).
After adjustment for severity of PAD (both groups with 
CLI before primary PTA), the clinical differences observed 
initially between the whole control group and restenosis 
group, as well as laboratory parameters differentiating both 
groups remained still significant (Table 4S, Table 5S).
Hemostatic variables
Higher thrombin generation (+ 7.9%) was observed in 
patients with restenosis (Table 2). ETP values in this group 
positively correlated with fibrinogen and CRP (r = 0.51, 
p = 0.0005 and r = 0.3, p = 0.003 respectively). Moreover, 
14.2% higher vWF antigen levels were found in the reste-
nosis group (Table 2). Among fibrinolysis proteins, active 
TAFI levels were 5% lower also in the restenosis group 
(p = 0.03).
Patients with CLI and restenosis had reduced clot perme-
ability (− 9.5%) and prolonged CLT (+ 12.4%) compared 
with the control group (Fig. 2).  Ks and CLT showed strong 
associations with fibrinogen (r = − 0.55, p < 0.0001 and 
r = 0.56, p < 0.001, respectively). CRP correlated with  Ks 
(r = − 0.36, p = 0.0016) and CLT (r = 0.32, p = 0.047). The 
univariate logistic analysis for Ks and CLT in the restenosis 
group is shown in Table 3.
CLT inversely correlated with ABI (r = − 0.21) and TBI 
(r = − 0.21) in all 132 patients (p < 0.05).
In the control group correlations between fibrinogen con-
centrations and Ks (r = − 0.55, p < 0.001) as well as CLT 
(r = 0.34, p = 0.03) were also observed.
Table 2  Laboratory parameters 
and fibrin clot properties 
measured in patients with 
restenosis and controls
Values are given as mean ± SD or median (IQR)
eGFR estimated glomerular filtration rate; CRP C-reactive protein; PAI-1 plasminogen activator inhibi-
tor-1; ETP endogenous thrombin potential; vWF von Willebrand factor; TAFI thrombin activatable fibrinol-
ysis inhibitor; tPA tissue-type plasminogen activator; Ks permeability coefficient; CLT clot lysis time
Restenosis group (n = 85) Controls (n = 47) p value
Creatinine, umol/l 87.58 ± 48.98 76.27 ± 23.6 0.076
eGFR, ml/min/1.73 m2 81.46 ± 33.96 94.17 ± 26.9 0.024
Hemoglobin, g/l 12.78 ± 1.71 13.85 ± 1.17 < 0.001
Platelets, x103/ul 231.35 ± 80.84 215.96 ± 43.62 0.16
Fibrinogen, g/l 3.84 ± 1.17 3.69 ± 0.63 0.87
CRP, mg/l 5.0 (1.74; 15.40) 5.0 (5.0; 8.2) 0.43
PAI-1, ng/ml 31.1 (25.45; 38.5) 31.8 (28.9; 34.9) 0.62
ETP (nM.min) 1568 (1445; 1691.5) 1441 (1362; 1568) < 0.001
vWF % 207 (167.5; 239.5) 180 (145; 204) < 0.001
TAFI ia/a % 96 (85; 107) 100 (94; 108) 0.03
Plasminogen (%) 105 (90.5; 121.5) 105 (97; 119) 0.98
α2-antiplasmin (%) 112.51 ± 17.01 109.77 ± 17.76 0.22
tPA Ag, ng/ml 10.81 ± 2.83 10.16 ± 1.98 0.12
Ks, 10−9cm2 6.38 ± 0.85 6.98 ± 0.79 < 0.001
CLT, min 107.24 ± 22.93 95.40 ± 15.46 0.003
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Follow‑up
During a mean follow-up of 24.3  months (range, 
12–36 months), 54 patients (63.5%) with CLI and reste-
nosis reached a composite endpoint including re-inter-
vention, amputation and death. 18 patients (21.2%) have 
died—mostly of cardiovascular events (heart failure, acute 
coronary syndrome). 38 patients (44.7%) had at least one 
re-intervention but only five patients lost the limb (5.8%). 
In the control group one patient died (2.1%), 8 underwent 
recurrent PTA because of restenosis (17%) and none had an 
amputation.
Patients with restenosis and worse outcomes had more 
frequent RF, smoking history, concomitant CAD and CVD. 
No differences in fibrin clot properties and other laboratory 
variables in this group were observed.
Discussion
This study demonstrates that altered plasma clot properties 
and impaired susceptibility to lysis are associated with the 
history of restenosis within the first year of endovascular 
treatment in PAD patients with CLI. In patients with CLI 
and restenosis plasma fibrin clots are less permeable and 
more resistant to lysis compared to those PAD patients 
who did not experience restenosis after ET. These findings 
extended our knowledge on the role of prothrombotic clot 
features and hypolysibility in advanced PAD.
Our results are consistent with previous investigations in 
patients with PAD without CLI [17, 18, 20]. While fibrin 
clots presented more prothrombotic features in CLI patients 
with restenosis, both groups did not differ according to main 
inflammatory determinants of clot characteristics, namely 
fibrinogen and CRP. However, increased levels of fibrino-
gen and CRP correlated with lower clot permeability and 
prolonged lysis, which is consistent with data from previous 
studies [14, 26].
Table 3  Univariate logistic analysis. Odds for lower quartile com-
pared to higher quartile of Ks and odds for upper quartile compared to 
lower quartile of CLT in the restenosis group
Ks CLT
Variable OR (95%CI) p value OR (95%CI) p value
Age 1.00 (0.94; 
1.07)
0.89 1.03 (0.97; 
1.11)
0.31
BMI 0.95 (0.82; 
1.07)
0.40 0.88 (0.75; 
1.02)
0.11
eGFR 1.01 (0.99; 
1.03)
0.46 0.99 (0.97; 
1.01)
0.31
Hematocrit 0.97 (0.84; 
1.11)
0.62 0.97 (0.84; 
1.10)
0.60
PLT 1.00 (0.99; 
1.01)
0.86 1.00 (1.00; 
1.01)
0.48
Fibrinogen 8.90 (2.90; 
49.01)
0.002 2.66 (1.43; 
6.04)
0.007
CRP 1.12 (1.04; 
1.23)
0.009 1.05 (1.00; 
1.13)
0.11
ABI 0.99 (0.19; 
3.95)
0.98 0.37 (0.04; 
1.82)
0.31
TBI 1.09 (0.99; 1.2) 0.09 0.99 (0.89; 
1.11)
0.95
Ks – – 0.06 (0.01; 
0.24)
0.001
CLT 1.10 (1.05; 
1.18)
0.001 – –
PAI-1 1.17 (1.07; 
1.31)
0.002 1.39 (1.19; 
1.76)
0.0005
ETP 1.02 (1.01; 
1.03)
0.004 1.01 (1.01; 
1.02)
0.0008
vWF % 1.01 (0.99; 
1.02)
0.39 1.01 (1.00; 
1.03)
0.19
TAFI 1.05 (1.01; 
1.11)
0.044 1.06 (1.02; 
1.13)
0.02
Plasminogen 0.95 (0.90; 
0.99)
0.02 0.97 (0.93; 
1.01)
0.11
α2-antiplasmin 0.99 (0.94; 
1.03)
0.48 0.98 (0.95; 
1.02)
0.37
tPA 1.03 (0.83; 
1.28)
0.77 0.96 (0.77; 
1.19)
0.69
AH 0.14 (0.02; 
0.75)
0.02 0.71 (0.12; 
3.67)
0.71
CAD 0.9 (0.24; 3.26) 0.87 1.47 (0.44; 
5.06)
0.67
MI 1.75 (0.36; 
8.69)
0.48 1.54 (0.42; 
5.81)
0.51
AF 0.49 (0.02; 
4.24)
0.53 4.71 (0.62; 
96.81)
0.14
CHF 6.9 (1.33; 
53.03)
0.02 4.5 (1.09; 
23.57)
0.03
DM 0.26 (0.06; 
0.98)
0.047 1.21 (0.36; 
4.16)
0.75
CVD 0.89 (0.75; 
1.33)
0.07 1.0 (0.24; 4.25) 1.0
Smoking 1.69 (0.43; 
7.45)
0.45 0.63 (0.15; 
2.40)
0.49
a In comparison to patients without mentioned co-morbidities and 
medical therapy
Abbreviations: see Tables 1 and 2
Table 3  (continued)
Ks CLT
RF 0.30 (0.04; 
1.46)
0.14 0.78 (0.19; 
3.13)
0.72
Statin 0.08 (0.001; 
0.86)
0.02 0.32 (0.002; 
6.31)
0.36





P2Y12 4.76 (1.31; 
22.9)
0.02 3.08 (0.96; 
11.08)
0.06
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In our data interpretation, several confounding factors 
should be addressed. We demonstrated that the involve-
ment of unfavorable fibrin clot properties in patients with 
CLI and restenosis is similar to that reported previously in 
individuals with re-occlusion (stent thrombosis) following 
stent implantation in the coronary arteries [25, 27]. However 
the mechanism of in-stent restenosis remains different than 
in-stent thrombosis. Most of the known causes of resteno-
sis produce acute or late stent thrombosis where incomplete 
endothelialization and persistent fibrin-rich thrombi play a 
crucial role [28]. It is difficult to determine what is the con-
tribution of thrombosis and inflammatory-related neointimal 
proliferation in restenosis among patients with PAD.
We also observed increased vWF especially in patients 
of the restenosis group. This marker was found as the inde-
pendent predictor of fibrin-rich intracoronary thrombus pres-
ence in patients with acute MI [29]. Moreover, the extent of 
vWF release in patients with acute coronary syndrome was 
an independent predictor of adverse clinical outcome [30]. 
Although previous observations of the association of vWF 
and restenosis in PAD are not consistent [31, 32], in the 
current study elevated levels of vWF in PAD patients could 
indicate on endothelial cell dysfunction and its contribution 
to restenosis process in PAD.
Thrombin generation was higher in CLI patients with 
restenosis and strongly correlated with fibrin clot param-
eters. Moreover, ETP constituted one of the independent 
predictors for low Ks values and high CLT values. This 
finding is consistent with observations that higher thrombin 
concentrations produce less permeable clots, composed of 
a dense fiber network resistant to lysis [33]. Elevated ETP 
could be involved in atherosclerosis and progression of PAD 
in part through fibrin-mediated mechanisms. Although in 
many studies in patients with CAD and fewer in patients 
with PAD thrombin generation (in vivo) and ETP (ex vivo) 
were altered, it is not clear how important is the relationship 
between high thrombin generation and atherosclerosis [34].
Patients were receiving antiplatelet drugs, and it is known 
that aspirin positively affects clot structure [35]. In our study 
altered plasma clot properties with more pronounced nega-
tive characteristics in the restenosis group were apparent 
despite aspirin and clopidogrel administration. The benefi-
cial effect of the statins on fibrin properties has also been 
described [36]. However, all patients in this study were tak-
ing statins and the impact of these medications could not 
have been assessed.
The choice of a 10% difference in CLT or clot permeabil-
ity as biologically important deserves a comment. We chose 
this difference based on our praevious studies using a simi-
lar methodology [37, 38]. Because of synergistic actions of 
multiple prothrombotic alterations 10–20% differences could 
be sufficient to modulate the hypercoagualable state. In our 
recent cohort study we reported that similar differences in 
fibrin clot properties have a prognostic value in terms of the 
risk of recurrent thromboembolism during follow-up [38].
Further studies are needed to validate clinical relevance 
of our findings among patients with CLI.
Limitations
This study has several limitations. First, the number of 
patients was limited, though the study was adequately pow-
ered however, the subgroup analysis especially with long 
outcomes should be interpreted with caution. Secondly, 
we did not analyze a potential impact of blood cells and 
platelets on fibrin clot structure/function. Third, other fibrin 
Fig. 2  Scatter plots of the permeability coefficient (Ks) and clot lysis time (CLT) measurements in patients with restenosis and control group. 
Lines represent mean values for both parameters, p < 0.005
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clot modifiers including oxidative stress and homocysteine 
have not been investigated in the current study either [18]. 
Although fibrin parameters can be changed by medical treat-
ment, we did not expect any differences of the impact of such 
management on these parameters since all patients and con-
trols were treated similarly. The important difference with 
antiplatelet and anticoagulation treatment was associated 
with the re-PTA procedure. Before endovascular procedure 
almost all CLI patients were taken  P2Y12 inhibitors and half 
of them received LMWH (Table 1). We did not measure 
anti-FXa activity before blood sampling to confirm that the 
patients receiving LMWH had no residual anticoagulant 
effects. However, > 12 h after the last injection, such effects 
are rather unlikely.
Finally, an important limitation is the way of recruit-
ment. All the patients were recruited after the primary 
endovascular procedure with a 12 months follow-up period. 
To achieve an adequate number of patients in the control 
group, we enrolled some patients with severe claudication 
(32%), what influenced on differences in PAD characteris-
tic between analyzed groups and could have an influence 
on some clinical outcomes. However after adjustment for 
the severity of PAD (both restenosis and control group with 
CLI), the clinical and laboratory differences observed ini-
tially between the whole control group and restenosis group 
remained significant.
Our findings cannot be easily extrapolated to patients 
with severe comorbidities, who were excluded from our 
study, particularly those with end-stage renal failure shown 
to alter plasma fibrin properties unfavorably [15, 16].
Conclusions
Our study demonstrates that fibrin clots in patients with 
CLI who experienced restenosis despite optimal endovas-
cular and pharmacological therapy are more prothrom-
botic involving denser fiber meshwork relatively resistant 
to lysis compared with those with good outcomes over a 
1 year follow-up. However, because of the complexity of 
interactions between cardiovascular risk factors, coagula-
tion proteins, platelets function and pharmacotherapy, our 
observation does not allow to determine which CLI patients 
with impaired fibrin clot properties would develop poor out-
comes. Further studies are required to confirm hypothetical 
benefits of prolonged anticoagulant therapy in this subgroup 
of patients.
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